During hepatitis B virus(HBV) infection host immune plays important role.Recently there are many different antiviral therapy methods.Different antiviral therapy methods showed different effector.In order to investigate whether these antiviral therapy methods especially methods directly inhibit viral replication have some effect on host immune the investigators designed these study. The investigators want to observe the change of host immune during antiviral therapy in patients with chronic HBV infection, and analyze the relationship between these changes and the antiviral effector of these drugs.
Study Type
INTERVENTIONAL
Allocation
NA
Masking
NONE
Enrollment
56
600mg,1/d,one year
Changhai Hospital
Shanghai, Shanghai Municipality, China
change of programmed death-1(PD-1) level of patients with chronic HBV infection during therapy
Time frame: base line-4 weeks-12 weeks-24 weeks-end of therapy
Decline of hepatitis B e antigen (HBeAg) level
Time frame: base line-4weeks-12weeks-24weeks-end of therapy
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.